CBPO - China Biologic Products Holdings, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
91.99
+1.59 (+1.76%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close90.40
Open90.21
Bid91.70 x 800
Ask103.00 x 900
Day's Range89.50 - 92.83
52 Week Range71.85 - 107.44
Volume162,826
Avg. Volume419,744
Market Cap3.058B
Beta1.29
PE Ratio (TTM)39.77
EPS (TTM)2.31
Earnings DateOct 31, 2018 - Nov 5, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est104.24
Trade prices are not sourced from all markets
  • See what the IHS Markit Score report has to say about China Biologic Products Holdings Inc.
    Markit6 days ago

    See what the IHS Markit Score report has to say about China Biologic Products Holdings Inc.

    Short interest is low for CBPO with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. ETFs that hold CBPO had net inflows of $132 million over the last one-month.

  • PR Newswire7 days ago

    China Biologic Names Bing Li as New CEO

    BEIJING, Aug. 13, 2018 /PRNewswire/ -- China Biologic Products Holdings, Inc. (CBPO) ("China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced that the Company's Board of Directors (the "Board") has appointed Dr. Bing Li as the Chief Executive Officer of the Company, effective August 13, 2018. Mr. Zhijun Tong, the former acting CEO, will continue to serve as an executive director of the Board and President of the Company.

  • Associated Press17 days ago

    China Biologic Products: 2Q Earnings Snapshot

    On a per-share basis, the Beijing-based company said it had profit of 83 cents. Earnings, adjusted for non-recurring costs, were $1.17 per share. The biopharmaceutical company posted revenue of $120.4 ...

  • PR Newswire17 days ago

    China Biologic Reports Financial Results for the Second Quarter of 2018

    -- 2Q18 Total Sales Up 25.5% YoY and Non-GAAP Adjusted Net Income Down 2.8% YoY in RMB terms, or   Total Sales Up 34.8% YoY to $120.4 Million and Net Income Down 7.7% YoY to $28.6 Million in USD terms ...

  • PR Newswire24 days ago

    China Biologic Products to Report Second Quarter 2018 Financial Results

    BEIJING , July 27, 2018 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO) ("China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical ...

  • Ping An Said to Mull Rival Takeover Offer for China Biologic
    Bloomberglast month

    Ping An Said to Mull Rival Takeover Offer for China Biologic

    Ping An Insurance (Group) Co., China’s largest insurer by market value, is considering a rival offer for plasma treatment provider China Biologic Products Holdings Inc., people familiar with the matter said. An arm of Ping An is in talks with other investors about a potential joint bid for Beijing-based China Biologic, according to the people, who asked not to be identified because the information is private. Any offer would be higher than the $110-per-share proposal from Chinese buyout firm Citic Capital, which valued U.S.-listed China Biologic at about $3.6 billion, the people said.

  • PR Newswire2 months ago

    China Biologic Announces Results of Its 2018 Annual General Meeting of Shareholders

    BEIJING, July 2, 2018 /PRNewswire/ -- China Biologic Products Holdings, Inc. (CBPO) ("CBPO" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced the results of the Company's 2018 Annual General Meeting of Shareholders (the "Annual Meeting"), which was originally convened at 10:00 a.m. on Friday, June 29, 2018, and adjourned and re-convened at 10:00 a.m. on Monday, July 2, 2018. At the Annual Meeting, shareholders of the Company approved the re-election of each of Mr. Yungang Lu and Mr. Zhijun Tong as a Class III director to serve on the board of directors of the Company (the "Board") until the 2021 annual general meeting of shareholders, and ratified the appointment of KPMG Huazhen LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2018.

  • Reuters2 months ago

    Ex-Warburg Pincus China head targets up to $1.5 bln for China fund - sources

    Private-equity firm Centurium Capital, founded by former Warburg Pincus China head, is targeting to raise up to $1.5 billion in its China-focused fund to invest in healthcare and consumer sectors, two sources with knowledge of the matter said. The fundraising by Centurium - set up by David Li after he had worked with the U.S. buyout firm for 14 years - adds to a massive industry-wide pool of money for acquisitions in China, which is popular among investors given its rapid urbanization and rising incomes.

  • ACCESSWIRE2 months ago

    Today’s Research Reports on Stocks to Watch: JD.com and China Biologic Products

    NEW YORK, NY / ACCESSWIRE / June 19, 2018 / JD.com and China Biologic Products Holdings both saw gains in Monday trading. JD.com saw a modest rise after Wall Street learned that Google is investing $550 ...

  • PR Newswire2 months ago

    China Biologic Announces Receipt of Non-Binding Acquisition Proposal

    BEIJING, June 19, 2018 /PRNewswire/ -- China Biologic Products Holdings, Inc. (CBPO) ("CBPO" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced that its board of directors (the "Board") has received an unsolicited, preliminary non-binding proposal letter from CCRE Holdings Limited, a wholly owned subsidiary of CITIC Capital Holdings Limited (together with its affiliates, "CITIC"), pursuant to which CITIC proposes to acquire all of the outstanding shares of the Company not already owned by CITIC for US$110 in cash per share. A copy of the proposal letter is attached hereto as Annex A.

  • PR Newswire2 months ago

    WeissLaw LLP Investigates China Biologic Products Holdings, Inc.

    NEW YORK , June 18, 2018 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of China Biologic Products Holdings, Inc. ...

  • Here's Why China Biologic Products Holdings Inc. Soared as Much as 25.8% Today
    Motley Fool2 months ago

    Here's Why China Biologic Products Holdings Inc. Soared as Much as 25.8% Today

    The Chinese plasma manufacturer might be acquired for $110 per share.

  • Stocks Slide; Intel Downgraded; JD.com Spikes On Google Deal
    Investor's Business Daily2 months ago

    Stocks Slide; Intel Downgraded; JD.com Spikes On Google Deal

    Stocks slid lower Monday as global markets remained rattled by the U.S.-China trade standoff. China stocks were highly active, however, led by JD.com.

  • Reuters2 months ago

    CITIC Capital offers to buy China Biologic for $110 per share

    A unit of Chinese investment firm CITIC Capital Holdings Ltd said on Monday it has offered to buy U.S.-listed biotech firm China Biologic Products Holdings Inc , in a deal valuing the company at $3.65 ...

  • Reuters2 months ago

    Investment firm CITIC Capital offers to buy China Biologic Products

    A unit of Chinese investment firm CITIC Capital Holdings Ltd has offered to buy U.S.-listed biotech firm China Biologic Products Holdings Inc. The unit, CCRE, offered $110 in cash for each share of China ...

  • PR Newswire2 months ago

    China Biologic Receives CFDA Clinical Trial Approval for Human Fibrin Sealant

    BEIJING, June 11, 2018 /PRNewswire/ -- China Biologic Products Holdings, Inc. (CBPO) ("China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced that Shandong Taibang Biological Products Co. Ltd., the Company's majority-owned subsidiary, recently obtained approval from the China Food and Drug Administration (the "CFDA") to begin human clinical trials on its Human Fibrin Sealant ("Fibrin Sealant") product. Fibrin Sealant is intended to be used as an adjunct to hemostasis on patients undergoing surgery in case traditional surgical techniques such as sutures, ligatures, and cauteries are ineffective or impractical.

  • GlobeNewswire2 months ago

    Analysis: Positioning to Benefit within China Biologic Products, Merus N.V, Adient, G1 Therapeutics, Westport Fuel, and AppFolio — Research Highlights Growth, Revenue, and Consolidated Results

    NEW YORK, June 06, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of China ...

  • Was China Biologic Products Holdings Inc’s (NASDAQ:CBPO) Earnings Decline Part Of A Broader Industry Downturn?
    Simply Wall St.3 months ago

    Was China Biologic Products Holdings Inc’s (NASDAQ:CBPO) Earnings Decline Part Of A Broader Industry Downturn?

    Assessing China Biologic Products Holdings Inc’s (NASDAQ:CBPO) performance as a company requires looking at more than just a years’ earnings data. Below, I will run you through a simple senseRead More...

  • ACCESSWIRE3 months ago

    Blog Exposure - Portola Pharma Receives Approval from FDA for Its Lead Candidate

    LONDON, UK / ACCESSWIRE / May 08, 2018 / If you want access to our free research report on Portola Pharma, Inc. (NASDAQ: PTLA), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=PTLA as the Company's latest news hit the wire. On May 03, 2018, the Company announced that the US Food and Drug Administration (FDA) has approved its lead candidate, Andexxa®, the first and only antidote indicated for patients treated with rivaroxaban and apixaban, when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding. Active-Investors.com is currently working on the research report for China Biologic Products Holdings, Inc. (NASDAQ: CBPO), which also belongs to the Healthcare sector as the Company Portola Pharma.

  • Associated Press4 months ago

    China Biologic Products: 1Q Earnings Snapshot

    On a per-share basis, the Beijing-based company said it had net income of 92 cents. Earnings, adjusted for non-recurring costs, came to $1.21 per share. The biopharmaceutical company posted revenue of ...

  • PR Newswire4 months ago

    China Biologic Reports Financial Results for the First Quarter of 2018

    --1Q18 Total Sales Up 13.7% YoY and Non-GAAP Adjusted Net Income Up 2.1% YoY in RMB terms, or  Total Sales Up 23.0% YoY to $112.5 Million and Net Income Up 5.3% YoY to $31.6 Million in USD terms-- BEIJING ...

  • Is There An Opportunity With China Biologic Products Holdings Inc’s (NASDAQ:CBPO) 39% Undervaluation?
    Simply Wall St.4 months ago

    Is There An Opportunity With China Biologic Products Holdings Inc’s (NASDAQ:CBPO) 39% Undervaluation?

    Does the share price for China Biologic Products Holdings Inc (NASDAQ:CBPO) reflect it’s really worth? Today, I will calculate the stock’s intrinsic value using the discounted cash flow (DCF) method.Read More...

  • Has China Biologic Products Holdings Inc (NASDAQ:CBPO) Got Enough Cash?
    Simply Wall St.4 months ago

    Has China Biologic Products Holdings Inc (NASDAQ:CBPO) Got Enough Cash?

    Stocks with market capitalization between $2B and $10B, such as China Biologic Products Holdings Inc (NASDAQ:CBPO) with a size of US$2.81B, do not attract as much attention from the investingRead More...

  • See what the IHS Markit Score report has to say about China Biologic Products Holdings Inc.
    Markit5 months ago

    See what the IHS Markit Score report has to say about China Biologic Products Holdings Inc.

    China Biologic Products Holdings Inc NASDAQ/NGS:CBPO